Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Shanghai Henlius Biotech, Inc.
上海復宏漢霖生物技術股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 2696)

POLL RESULTS OF THE RESOLUTIONS PROPOSED AT THE 2026 FIRST EXTRAORDINARY GENERAL MEETING HELD ON MONDAY, 23 NOVEMBER 2026

The board (the "**Board**") of directors (the "**Directors**") of Shanghai Henlius Biotech, Inc. (the "**Company**") is pleased to announce the poll results of the 2026 first extraordinary general meeting (the "**EGM**") held at Conference Room, 10th Floor, B8 Building, No. 188 Yizhou Road, Xuhui District, Shanghai, the People's Republic of China ("**PRC**") at 2:00 p.m. on Monday, 23 November 2026.

References are made to the notice and the circular (the **"Circular**") of the Company both dated 2 November 2026 in relation to the EGM. Unless the context otherwise requires, capitalised terms used in this announcement shall have the same meanings as those defined in the Circular.

EGM

As at the date of the EGM, the total number of the issued shares of the Company (the "**Shares**") was 545,297,728 Shares, comprising 197,420,456 Unlisted Shares and 347,877,272 H Shares, all of which entitled the holders (or authorised representatives) to attend and vote on the resolutions proposed at the EGM (the "**Resolutions**"). Shareholders or authorised representatives holding an aggregate of 407,808,516 Shares with voting rights, representing approximately 74.786396% of the total number of the Shares with voting rights of the Company were present at the EGM. All Directors attended the EGM.

As disclosed in the Circular, Fosun Pharma Industrial Development, Fosun New Medicine and Fosun Industrial, which are subsidiaries of Fosun Pharma, were required to abstain from voting on Resolution 1 at the EGM. As at the date of the EGM, Fosun Pharma Industrial Development, Fosun New Medicine, Fosun Industrial and their respective associates, which were interested in an aggregate of 344,730,800 Shares, representing approximately 63.218822% of the total issued Shares of the Company, and had abstained from voting on Resolution 1.

Save as disclosed above, to the best of the Directors' knowledge, information and belief, having made all reasonable enquiries, no Shareholder was required to abstain from voting on the Resolutions under the Listing Rules. There was no Share entitling the holder to attend the EGM and abstain from voting in favour of the Resolutions under Rule 13.40 of the Listing Rules. No Shareholder has stated the intention in the Circular to vote against or to abstain from voting on the Resolutions.

Pursuant to the Listing Rules and the Articles of Association, Computershare Hong Kong Investor Services Limited, representatives from the Shareholders and a member of the board of supervisors of the Company acted as the scrutineers for vote tabulation at the EGM.

The EGM was convened in compliance with the requirements of the Company Law of PRC and the Articles of Association. Dr. Xingli Wang, chairman of the Board, acted as the chairman of the EGM.

POLL RESULTS OF THE EGM

The poll results in respect of the Resolutions are as follows:

Ordinary Resolutions		**Number of valid votes and percentage of total number of votes (%)**		
		For	**Against**	**Abstain**
1.	To consider and, if thought fit, approve the revision of the annual cap for the collaboration arrangements under the HLX01 Agreement; and to authorise any Director to exercise all powers which they consider necessary and do such other acts and things and execute such other documents which in their opinion may be necessary or desirable to implement the revision of the annual cap for the collaboration arrangements under the HLX01 Agreement.	63,058,417 (95.459567%)	2 (0.000003%)	2,999,305 (4.540430%)
	As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.			
2.	To consider and approve the resolution in relation to the appointment of Mr. Zhi Huang as a non-executive director of the Company.	407,540,870 (99.934370%)	248,346 (0.060897%)	19,300 (0.004733%)
	As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.			

Ordinary Resolutions		Number of valid votes and percentage of total number of votes (%)		
		For	**Against**	**Abstain**
3.	To consider and approve the resolution in relation to the appointment of Dr. Huajun Chen as an independent non-executive director of the Company.	407,721,816 (99.978740%)	67,400 (0.016527%)	19,300 (0.004733%)
	As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.			

On behalf of the Board
Shanghai Henlius Biotech, Inc.
Xingli Wang
Chairman

Hong Kong, 23 November 2026

As at the date of this announcement, the board of directors of the Company comprises Dr. Xingli Wang as the chairman and non-executive director, Dr. Jun Zhu as the executive director, Mr. Qiyu Chen, Mr. Yuqing Chen, Ms. Xiaohui Guan, Dr. Yi Liu and Mr. Zhi Huang as the non-executive directors, and Mr. Tak Young So, Dr. Lik Yuen Chan, Dr. Ruilin Song and Dr. Huajun Chen as the independent non-executive directors.